Suppr超能文献

胸苷酸合成酶多态性对接受新辅助放化疗的直肠癌患者的预后意义。

Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.

机构信息

Department of Medical Oncology, Complejo Hospitalario de Navarra, Navarra Health Service, Navarra, Spain.

出版信息

Colorectal Dis. 2013 Apr;15(4):428-35. doi: 10.1111/codi.12009.

Abstract

AIM

There is a lack of prognostic factors of preoperative chemoradiation for locally advanced rectal cancer. Thymidylate synthase (TS) is the most important target of 5-fluorouracil; three main genetic polymorphisms of TS have been described. We analysed the prognostic value of these in patients with locally advanced rectal cancer treated with fluoropyrimidine-based chemoradiation.

METHOD

Ninety-nine patients treated between November 2001 and March 2009 were included. All were treated by radiotherapy (5040 cGy) and concomitant fluoropyrimidine-based chemotherapy. Three polymorphisms were analysed: (i) a double (2R) or triple (3R) repeat of a 28 base pair (bp) tandem sequence upstream of the ATG codon initiation site in the 5'-terminal regulatory region, (ii) a functional G > C single nucleotide polymorphism present in the second repeat of the 3R alleles and (iii) a 6 bp deletion at nucleotide 1494 in the 3'-untranslated region. DNA was extracted from paraffin-embedded core biopsies taken from the tumour and the genotype was analysed using polymerase chain reaction restriction fragment length polymorphism.

RESULTS

The 6 bp polymorphism was significantly associated with disease-free survival (+ 6 bp/+ 6 bp vs-6 bp/-6 bp, P = 0.032 logistic regression). No differences were found in disease-free survival according to the other polymorphisms studied. No relationship was observed between the different TS genotypes and pathological regression.

CONCLUSION

The study suggests that the TS 6 bp polymorphism may be a predictor of disease-free survival in patients with locally advanced rectal cancer treated with fluoropyrimidine-based chemoradiation.

摘要

目的

局部进展期直肠癌术前放化疗缺乏预后因素。胸苷酸合成酶(TS)是氟尿嘧啶最重要的靶点;已描述了 TS 的三个主要遗传多态性。我们分析了这些多态性在接受氟嘧啶为基础的放化疗的局部进展期直肠癌患者中的预后价值。

方法

纳入了 2001 年 11 月至 2009 年 3 月期间接受治疗的 99 例患者。所有患者均接受了放疗(5040 cGy)和氟嘧啶为基础的同步化疗。分析了三种多态性:(i)在 ATG 起始密码子上游的 5'端调控区 28 个碱基对(bp)串联序列的双(2R)或三(3R)重复,(ii)在 3R 等位基因的第二个重复中存在的功能性 G > C 单核苷酸多态性,(iii)在 3'非翻译区的核苷酸 1494 处的 6bp 缺失。从肿瘤处取石蜡包埋核心活检标本提取 DNA,并用聚合酶链反应限制片段长度多态性分析基因型。

结果

6bp 多态性与无病生存率显著相关(+6bp/+6bp vs-6bp/-6bp,P=0.032 逻辑回归)。根据研究的其他多态性,无病生存率无差异。不同 TS 基因型与病理缓解之间无相关性。

结论

该研究表明,TS 6bp 多态性可能是氟嘧啶为基础的放化疗局部进展期直肠癌患者无病生存率的预测因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验